A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).

被引：0
|
作者：
Zinzani, PL [1 ]
机构：
[1] Univ Bologna, Inst Hematol & Med Oncol L & A Seranoli, I-40126 Bologna, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
344
引用
收藏
页码：93A / 93A
页数：1
相关论文
共 50 条
  • [21] LONG TERM OUTCOME OF PATIENTS WITH GASTRIC MARGINAL ZONE LYMPHOMA RECEIVING FLUDARABINE, MITOXANTRONE AND RITUXIMAB AS FIRST-LINE TREATMENT
    Cencini, E.
    Fabbri, A.
    Bartalucci, G.
    Schiattone, L.
    Gozzetti, A.
    Lauria, F.
    Bocchia, M.
    HAEMATOLOGICA, 2015, 100 : 710 - 710
  • [22] BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA: EVIDENCE FROM A MULTICENTER, RETROSPECTIVE STUDY
    Mondello, P.
    Steiner, N.
    Willenbacher, W.
    Wasle, I.
    Zaja, F.
    Zambello, R.
    Visentin, A.
    Mauro, E.
    Ferrero, S.
    Ghione, P.
    Pitini, V.
    Cuzzocrea, S.
    Mian, M.
    HAEMATOLOGICA, 2016, 101 : 276 - 276
  • [23] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Wasle, Ines
    Zaja, Francesco
    Zambello, Renato
    Visentin, Andrea
    Mauro, Endri
    Ferrero, Simone
    Ghione, Paola
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1107 - 1114
  • [24] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
    Patrizia Mondello
    Normann Steiner
    Wolfgang Willenbacher
    Ines Wasle
    Francesco Zaja
    Renato Zambello
    Andrea Visentin
    Endri Mauro
    Simone Ferrero
    Paola Ghione
    Vincenzo Pitini
    Salvatore Cuzzocrea
    Michael Mian
    Annals of Hematology, 2016, 95 : 1107 - 1114
  • [25] Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL).
    Rummel, Mathias J.
    von Gruenhagen, Ulrich
    Niederle, Norbert
    Ballo, Harald
    Weidmann, Eckhart
    Welslau, Manfred
    Heil, Gerhard
    Balser, Christina
    Duerk, Heinz A.
    Stauch, Martina
    Kofahl-Krause, Dorothea
    Kaiser, Ulrich
    Knauf, Wolfgang
    Brugger, Wolfram
    BLOOD, 2008, 112 (11) : 900 - 900
  • [26] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM)
    Bosch, Francesc
    Villamor, Neus
    Abrisqueta, Pau
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Montserrat, Emili
    BLOOD, 2010, 116 (21) : 594 - 595
  • [27] Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas - First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)
    Rummel, Mathias J.
    Von Gruenhagen, U.
    Niederle, N.
    Rothmann, F.
    Ballo, H.
    Weidmann, E.
    Welslau, M.
    Heil, G.
    Duerk, H.
    Stauch, M.
    Losem, C.
    Matzdorff, A.
    Balser, C.
    Schalk, K.
    Kofahl-Krause, D.
    Kaiser, U.
    Knauf, W.
    Banat, A.
    Hoelzer, D.
    Brugger, W.
    BLOOD, 2007, 110 (11) : 120A - 120A
  • [28] Rituximab maintenance after R-CHOP in the first-line treatment of follicular lymphoma: A GOTEL phase II trial
    Rueda, A.
    Provencio, M.
    Abrio, M.
    Gomez-Codina, J.
    Llanos, M.
    Delgado, J.
    Rifa, J.
    Sabin, P.
    Velez de Mendizabal, E.
    Baz, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
    Sabater, E.
    Rueda, A.
    Salar, A.
    Lopez-Guillermo, A.
    Oyagueez, I.
    Collar, J. M.
    HAEMATOLOGICA, 2014, 99 : 487 - 488
  • [30] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
    Rummel, Mathias J.
    Niederle, Norbert
    Maschmeyer, Georg
    Banat, G. Andre
    von Gruenhagen, Ulrich
    Losem, Christoph
    Kofahl-Krause, Dorothea
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz
    Ballo, Harald
    Stauch, Martina
    Roller, Fritz
    Barth, Juergen
    Hoelzer, Dieter
    Hinke, Axel
    Brugger, Wolfram
    LANCET, 2013, 381 (9873): : 1203 - 1210
12345